Several other research firms also recently issued reports on HSKA. ValuEngine downgraded Heska from a buy rating to a hold rating in a research report on Wednesday, May 1st. Guggenheim initiated coverage on shares of Heska in a report on Thursday, May 23rd. They issued a neutral rating on the stock. Canaccord Genuity reaffirmed a buy rating and issued a $118.00 price target on shares of Heska in a report on Wednesday, February 20th. B. Riley decreased their price target on shares of Heska from $93.00 to $87.00 and set a neutral rating on the stock in a report on Wednesday, February 27th. Finally, Sidoti cut shares of Heska from a buy rating to a neutral rating in a report on Tuesday, February 26th. One research analyst has rated the stock with a sell rating, six have given a hold rating and one has issued a buy rating to the stock. The stock currently has an average rating of Hold and an average target price of $109.00.
Shares of NASDAQ HSKA traded up $0.25 during midday trading on Thursday, reaching $78.15. The company’s stock had a trading volume of 331 shares, compared to its average volume of 84,242. Heska has a 12-month low of $68.74 and a 12-month high of $114.50. The company has a market capitalization of $601.99 million, a PE ratio of 54.93 and a beta of 0.84. The company has a quick ratio of 1.45, a current ratio of 2.66 and a debt-to-equity ratio of 0.04.
Heska (NASDAQ:HSKA) last announced its earnings results on Tuesday, May 7th. The medical research company reported $0.10 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.19. Heska had a return on equity of 8.36% and a net margin of 3.63%. The firm had revenue of $29.51 million for the quarter, compared to the consensus estimate of $35.21 million. As a group, research analysts expect that Heska will post 0.03 EPS for the current fiscal year.
In other news, Director Scott Humphrey purchased 1,000 shares of the firm’s stock in a transaction dated Thursday, May 30th. The shares were purchased at an average price of $73.79 per share, with a total value of $73,790.00. Following the completion of the acquisition, the director now owns 3,062 shares in the company, valued at approximately $225,944.98. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. Corporate insiders own 14.00% of the company’s stock.
Several institutional investors have recently added to or reduced their stakes in the company. BlackRock Inc. grew its stake in Heska by 0.8% during the fourth quarter. BlackRock Inc. now owns 1,075,438 shares of the medical research company’s stock worth $92,596,000 after buying an additional 8,460 shares during the period. FMR LLC grew its position in shares of Heska by 2.0% during the first quarter. FMR LLC now owns 453,664 shares of the medical research company’s stock worth $38,616,000 after acquiring an additional 8,870 shares during the last quarter. Dimensional Fund Advisors LP grew its position in Heska by 5.9% in the 1st quarter. Dimensional Fund Advisors LP now owns 232,279 shares of the medical research company’s stock valued at $19,771,000 after buying an additional 12,849 shares in the last quarter. Ranger Investment Management L.P. lifted its holdings in Heska by 165.9% in the 4th quarter. Ranger Investment Management L.P. now owns 229,760 shares of the medical research company’s stock valued at $19,782,000 after acquiring an additional 143,359 shares during the last quarter. Finally, Redmile Group LLC lifted its holdings in Heska by 14.3% in the 1st quarter. Redmile Group LLC now owns 226,013 shares of the medical research company’s stock valued at $19,238,000 after acquiring an additional 28,300 shares during the last quarter. 88.96% of the stock is currently owned by hedge funds and other institutional investors.
Heska Corporation manufactures, sells, and markets veterinary diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Europe, and internationally. The company's Core Companion Animal segment offers Element DC and DRI-CHEM 7000 veterinary chemistry analyzers for blood chemistry and electrolyte analysis; Element HT5 and HemaTrue veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; Element i immunodiagnostic analyzers; Element COAG veterinary analyzers; and IV infusion pumps.
Further Reading: Sell-Side Analysts
Receive News & Ratings for Heska Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska and related companies with MarketBeat.com's FREE daily email newsletter.